Dovato and Fluvoxamine Tablets
Determining the interaction of Dovato and Fluvoxamine Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Theoretically, coadministration with inhibitors of UGT1A or CYP450 3A4 isoenzymes may increase the plasma concentrations of dolutegravir, which is primarily metabolized by UGT1A1 with some contribution from CYP450 3A4. Dolutegravir is also a substrate of UGT1A3, UGT1A9, and P-glycoprotein in vitro. Potent CYP450 3A4 inhibitors such as boceprevir (800 mg every 8 hours) and telaprevir (750 mg every 8 hours) had no significant effects on the pharmacokinetics of dolutegravir given at 50 mg once daily. The interaction has not been studied or reported with UGT1A1 inhibitors such as nilotinib, regorafenib, and sorafenib. However, it is possible that simultaneous inhibition of UGT1A1 and CYP450 3A4 may lead to a clinically significant interaction with dolutegravir. In 12 study subjects, administration of dolutegravir (30 mg once daily) with the dual UGT1A1 and CYP450 3A4 inhibitor, atazanavir (400 mg once daily), increased dolutegravir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin; 24 hours postdose) by 50%, 91% and 180%, respectively, compared to administration without atazanavir. When the same dosage of dolutegravir was given with atazanavir/ritonavir 300 mg/100 mg once daily, the Cmax, AUC and Cmin of dolutegravir increased by 34%, 62% an 121%, respectively. Because safety data regarding increased dolutegravir exposures are limited, caution may be advisable if dolutegravir is used in combination with both a UGT1A1 inhibitor and a CYP450 3A4 inhibitor.
- "Product Information. Tivicay (dolutegravir)." ViiV Healthcare, Research Triangle Park, NC.
Generic Name: fluvoxamine
Brand name: Luvox, Luvox CR
Synonyms: Fluvoxamine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dovato-Fluxid
- Dovato-Fluzone
- Dovato-Fluzone 2013-2014 Formula
- Dovato-Fluzone 2015-2016 Formula
- Dovato-Fluzone High Dose 2015-2016 Formula
- Dovato-Fluzone High-Dose
- Fluvoxamine Tablets-Dovobet
- Fluvoxamine Tablets-Dovonex
- Fluvoxamine Tablets-Dovonex (Calcipotriene Cream and Ointment)
- Fluvoxamine Tablets-Dovonex (Calcipotriene Scalp Solution)
- Fluvoxamine Tablets-Dovonex Cream
- Fluvoxamine Tablets-Dovonex Ointment